Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

Not Yet Recruiting

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants - IM037-009

Updated: 11 September, 2020   |   ClinicalTrials.gov

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1

    Phase

  • Gender(s)

  • 21-65

    Age Range

  • 1

    Location(s)

  • Not Yet Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: Part A SAD Cohort A2
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part A SAD Cohort A3
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part A SAD Cohort A4
Drug: BMS-986337 Other: BMS-986337 Placebo
Experimental: Part A SAD Cohort A5
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part A SAD Cohort A6
Biological: Famotidine Drug: BMS-986337
Experimental: Part A Single Ascending Dose (SAD) Cohort A1
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part B MAD Cohort B2
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part B MAD Cohort B3
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part B MAD Cohort B4
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part B Multiple Ascending Dose (MAD) Cohort B1
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part C MAD in Japanese Healthy participants Cohort C1
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part C MAD in Japanese Healthy participants Cohort C2
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part C MAD in Japanese Healthy participants Cohort C3
Other: BMS-986337 Placebo Drug: BMS-986337

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: - No clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations - For Japanese cohorts in Part C, must be first-generation Japanese (born in Japan, not living outside of Japan for more than 10 years, and both parents are ethnically Japanese) - Body mass index (BMI) of 18.0 kg/m^2 to 30.0 kg/m^2, inclusive, at screening; BMI = weight (kg)/height (m)^2 - Women and men must agree to follow specific methods of contraception, if applicable Exclusion Criteria: - Women who are of childbearing potential - Women who are breastfeeding - Prior exposure to BMS-986278 - Positive nasopharyngeal reverse transcriptase polymerase chain reaction (RT-PCR) test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on Day -2 Other protocol-defined inclusion/exclusion criteria apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com